Update on Clinical Trials in Systemic Lupus Erythematosus

Sonali Narain; Richard Furie


Curr Opin Rheumatol. 2016;28(5):477-487. 

In This Article

Ruplizumab (BG9588) and IDEC-131

Anti-CD40L antibodies have been studied in both lupus nephritis[61] and nonrenal lupus.[62,63] BG9588, an anti-CD40L antibody from Biogen, was evaluated in proliferative lupus nephritis. The study[64] was prematurely terminated because of thromboembolic events, later attributed to the binding of the drug's Fc receptor to platelet Immunoglobulin g Fc Receptor IIA. Preliminary analyses showed the improvement in hematuria and proteinuria, complement levels and dsDNA antibodies. IDEC-131 was evaluated in patients with mild-to-moderate SLE.[63] Although no thromboembolic events were observed, the study failed to meet its end points. Dapirolizumab (CDP 7657), a new anti-CD40L antibody, has a pegylated Fab' fragment and lacks the Fc portion, thus considered safer than its predecessor. A 32-week study[65] of dapirolizumab in 24 SLE patients reported minor adverse events and no thromboembolic events. Exploratory analysis showed a trend toward improved disease activity in the treatment group. Dapirolizumab is advancing to the next phase of development.